LivaNova (NASDAQ:LIVN) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPS

LivaNova (NASDAQ:LIVN) posted its quarterly earnings results on Wednesday. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.80 by $0.06, FiscalAI reports. The firm had revenue of $360.86 million for the quarter, compared to the consensus estimate of $354.31 million. LivaNova had a negative net margin of 16.12% and a positive return on equity of 15.98%. The business’s revenue was up 12.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.81 earnings per share. LivaNova updated its FY 2026 guidance to 4.150-4.250 EPS.

Here are the key takeaways from LivaNova’s conference call:

• The company reported double-digit organic revenue growth and 150 basis points of adjusted operating margin expansion in 2025, with strong cash generation and a 2026 revenue guide of +6% to +7% consistent with its Investor Day framework.
• LivaNova advanced its obstructive sleep apnea (OSA) program with a planned PMA approval for the clinical device in H1 2026, a follow-on MRI-compatible supplement and a commercial rollout targeting 2027, while highlighting the OSPREY RCT and the PolySync algorithm that management says can convert many non-responders.
• Epilepsy benefits from two near-term tailwinds: the CORE‑VNS clinical data
• Near‑term risks include third‑party component constraints for oxygenators, higher capital and R&D spend (2026 capex guidance ~$120M) to scale manufacturing and advance OSA, modest tariff exposure, and a reserved SNIA-related cash obligation (~$400M potential Q3 payment) that management says remains the company’s best estimate of the liability.

LivaNova Price Performance

LIVN traded down $0.28 during trading on Thursday, hitting $70.01. The company’s stock had a trading volume of 43,498 shares, compared to its average volume of 709,953. The company has a quick ratio of 1.12, a current ratio of 1.33 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $3.82 billion, a price-to-earnings ratio of -17.48 and a beta of 0.97. The firm’s 50 day moving average price is $64.41 and its two-hundred day moving average price is $58.81. LivaNova has a 12 month low of $32.48 and a 12 month high of $71.34.

Analysts Set New Price Targets

A number of research firms recently weighed in on LIVN. Stifel Nicolaus set a $80.00 target price on shares of LivaNova in a research note on Wednesday. Wall Street Zen raised LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. The Goldman Sachs Group reissued a “neutral” rating and issued a $66.00 target price on shares of LivaNova in a report on Friday, January 9th. Barclays raised their target price on LivaNova from $58.00 to $67.00 and gave the stock an “equal weight” rating in a research report on Friday, January 9th. Finally, Mizuho upped their price target on LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $74.11.

Key Stories Impacting LivaNova

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q4 beat — LivaNova reported adjusted EPS of $0.86 vs. consensus $0.80 and revenue of $360.9M (up ~12% year-over-year), outpacing Street estimates. LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
• Positive Sentiment: Raised FY‑2026 guidance — management now guides EPS $4.15–$4.25 versus consensus ~$3.90, signaling stronger expected profitability for the year. LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
• Positive Sentiment: Analyst upgrade/price target lift — Needham raised its price target to $81 with a Buy rating, reflecting upside to the new guidance and margin outlook. LIVN PT Raised to $81 at Needham
• Positive Sentiment: Short interest dropped — short interest fell ~16.6% in February to ~2.03M shares (≈3.7% of float), lowering short-squeeze risk and supporting upside momentum.
• Neutral Sentiment: Growth outlook & product cadence — management outlined 6%–7% revenue growth for 2026 and highlighted core-business expansion plus an upcoming OSA launch that could drive medium-term growth. LivaNova outlines 6%–7% revenue growth for 2026
• Neutral Sentiment: Strategic data partnership — coverage discussed a data partnership with Orrum that could improve clinical evidence/positioning in cardiac care, but impact timing is unclear. Could LivaNova’s (LIVN) Data Partnership With Orrum Quietly Reshape Its Cardiac Care Narrative?
• Negative Sentiment: Profitability nuance — GAAP diluted EPS ($0.56) and a reported negative net margin (~16.1%) highlight remaining cost/one‑time items and indicate adjusted results still mask GAAP profitability pressures. LivaNova Q4 earnings snapshot / transcript

Institutional Investors Weigh In On LivaNova

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State of Wyoming acquired a new position in shares of LivaNova during the second quarter worth approximately $31,000. EverSource Wealth Advisors LLC increased its stake in shares of LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after buying an additional 639 shares during the period. Quarry LP acquired a new position in shares of LivaNova during the third quarter valued at $36,000. UMB Bank n.a. boosted its holdings in LivaNova by 22.6% in the fourth quarter. UMB Bank n.a. now owns 971 shares of the company’s stock valued at $60,000 after acquiring an additional 179 shares during the last quarter. Finally, Johnson Financial Group Inc. acquired a new stake in LivaNova in the third quarter worth about $63,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.

Featured Articles

• Five stocks we like better than LivaNova
• ALERT: Drop these 5 stocks before the market opens tomorrow!
• MAJOR BUY ALERT: Mar-a-Lago/Trump/Elon
• Gilder: Don’t Buy AI Stocks, Do This Instead
• Read this or regret it forever
• What Expenses Can Be Deducted From Capital Gains Tax This Year?